News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Euthymics Bioscience, Inc. Initiates Clinical Trial for New Drug Targeted for Adult Attention Deficit Hyperactivity Disorder (ADHD)



3/22/2012 6:35:07 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Euthymics Bioscience, Inc. today announced that it has initiated a Phase 1 clinical trial of EB-1020, a next-generation drug in development for treating adult attention deficit hyperactivity disorder (ADHD), with low risk of drug abuse liability. This would meet a critical need because current stimulants used to treat ADHD are tightly regulated and often in short supply due to their addictive properties. Peer-reviewed preclinical data demonstrated that EB-1020 affects areas of the brain associated with ADHD. Dosing of healthy volunteers in the EB-1020 Phase 1 trial is now underway. Final results of the study are expected late this summer.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES